Foreword to: Microvascular Disease in Diabetes |
|
xv | |
Editor Biography |
|
xvii | |
List of Contributors |
|
xix | |
1 Introduction |
|
1 | (4) |
|
|
|
|
3 | (2) |
2 Pathophysiology |
|
5 | (18) |
|
|
|
5 | (1) |
|
Anatomo-Physiology of Microvessels |
|
|
5 | (1) |
|
Regulation of Microvascular Tone |
|
|
6 | (2) |
|
Endothelial-Dependent Vasodilation |
|
|
6 | (1) |
|
Endothelial-Independent Vasodilation |
|
|
6 | (1) |
|
|
7 | (1) |
|
|
7 | (1) |
|
|
7 | (1) |
|
Venoarteriolar Response (VAR) |
|
|
8 | (1) |
|
Structural Changes in the Microcirculation |
|
|
8 | (1) |
|
Functional Changes in the Microcirculation |
|
|
8 | (8) |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
Defective Myogenic Response |
|
|
10 | (1) |
|
Reduced Functional Hyperemia |
|
|
10 | (1) |
|
|
11 | (1) |
|
Role of the Immune System and Leukostasis |
|
|
11 | (1) |
|
|
12 | (3) |
|
|
12 | (1) |
|
|
12 | (1) |
|
|
13 | (1) |
|
|
13 | (1) |
|
Transforming Growth Factor (TGF)-β |
|
|
14 | (1) |
|
|
14 | (1) |
|
|
14 | (1) |
|
|
14 | (1) |
|
Vasoconstrictor Prostanoid Synthesis |
|
|
15 | (1) |
|
Role of Insulin Resistance |
|
|
15 | (1) |
|
|
15 | (1) |
|
|
16 | (7) |
3 Genetics of Diabetic Microvascular Disease |
|
23 | (22) |
|
|
|
|
23 | (1) |
|
|
23 | (7) |
|
|
23 | (1) |
|
|
24 | (1) |
|
|
25 | (1) |
|
Genome-Wide Association Studies on DKD |
|
|
25 | (4) |
|
Sequencing Efforts for DKD |
|
|
29 | (1) |
|
Genetics of Diabetic Retinopathy |
|
|
30 | (3) |
|
Heritability of Diabetic Retinopathy |
|
|
30 | (1) |
|
Candidate Genes for Diabetic Retinopathy |
|
|
30 | (1) |
|
Linkage Studies for Diabetic Retinopathy |
|
|
31 | (1) |
|
GWAS on Diabetic Retinopathy |
|
|
31 | (2) |
|
Sequencing Efforts for Diabetic Retinopathy |
|
|
33 | (1) |
|
Genetics of Diabetic Neuropathy |
|
|
33 | (1) |
|
Heritability of Diabetic Neuropathy |
|
|
33 | (1) |
|
Candidate Genes for Diabetic Neuropathy |
|
|
33 | (1) |
|
GWASs on Diabetic Neuropathy |
|
|
34 | (1) |
|
|
34 | (3) |
|
Larger Studies Are Needed |
|
|
34 | (1) |
|
How to Define the Phenotype? |
|
|
35 | (1) |
|
Variability in the Phenotypic Definitions |
|
|
35 | (1) |
|
|
36 | (1) |
|
Do Genetics of Microvascular Complications in T1D and T2D Differ? |
|
|
36 | (1) |
|
Low-Frequency and Rare Variants May Affect Diabetic Complications |
|
|
36 | (1) |
|
Sequencing of Rare and Low-Frequency Variants |
|
|
36 | (1) |
|
Linkage Analysis with GWAS Data |
|
|
37 | (1) |
|
Genetics May Reveal Biology and Infer Causality |
|
|
37 | (1) |
|
|
37 | (1) |
|
|
37 | (8) |
4 Epigenetics of Diabetic Microvascular Disease |
|
45 | (14) |
|
|
Diabetic Complications Include Microvascular and Macrovascular Injury |
|
|
45 | (1) |
|
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study in Type 1 Diabetic Patients, and the UKPDS Study in Type 2 Diabetic Patients, Support the Existence of the Hyperglycemic Memory Phenomenon |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
Models of Hyperglycemic Memory |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (4) |
|
|
49 | (1) |
|
Histone Methylation in Models of Hyperglycemic Variability |
|
|
49 | (1) |
|
Epigenetic Changes in Microvascular Models of Glycemic Memory |
|
|
50 | (2) |
|
miRNAs Contribute to the Control of Glucose Homeostasis and Are Dysregulated in Diabetes |
|
|
52 | (1) |
|
|
52 | (2) |
|
|
54 | (5) |
5 Diabetic Retinopathy - Clinical |
|
59 | (20) |
|
|
|
|
|
|
59 | (1) |
|
|
60 | (1) |
|
|
60 | (1) |
|
|
61 | (1) |
|
|
61 | (8) |
|
Non-Proliferative Diabetic Retinopathy (NPDR) |
|
|
61 | (4) |
|
|
62 | (2) |
|
|
64 | (1) |
|
|
65 | (1) |
|
Proliferative Diabetic Retinopathy (PDR) |
|
|
65 | (4) |
|
|
65 | (2) |
|
|
67 | (1) |
|
|
67 | (2) |
|
Diabetic Macular Edema (DME) |
|
|
69 | (4) |
|
|
70 | (31) |
|
|
71 | (1) |
|
|
71 | (1) |
|
|
71 | (2) |
|
|
73 | (1) |
|
|
74 | (5) |
6 Diabetic Retinopathy - Research |
|
79 | (6) |
|
|
Retina and Induction of Hyperglycemia |
|
|
79 | (1) |
|
Hyperglycemia and Retinal Microvasculature |
|
|
80 | (1) |
|
Hyperglycemia and Reactive Gliosis |
|
|
80 | (1) |
|
Hyperglycemia and Neurodegeneration |
|
|
81 | (1) |
|
Hyperglycemia and Inflammation |
|
|
81 | (1) |
|
|
82 | (3) |
7 Diabetic Nephropathy - Clinical |
|
85 | (12) |
|
|
|
85 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
87 | (1) |
|
|
88 | (1) |
|
|
89 | (1) |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
92 | (5) |
8 Diabetic Nephropathy - Research |
|
97 | (14) |
|
|
|
Essential Hypertension and DN |
|
|
97 | (2) |
|
Role of Genetics in the Pathogenesis of DN |
|
|
99 | (1) |
|
Polyol Pathway and Non-Enzymatic Glycation |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
101 | (1) |
|
Sodium-Glucose Cotransporter-2 (SGLT2) and DN |
|
|
101 | (1) |
|
|
101 | (1) |
|
|
102 | (1) |
|
DN in Induced Model of Type 1 Diabetes Mellitus (T1DM) |
|
|
102 | (1) |
|
DN in Spontaneous Model of T1DM |
|
|
103 | (1) |
|
|
103 | (1) |
|
Non-Obese Diabetic (NOD) Mice |
|
|
104 | (1) |
|
OVE26 Friend leukemia virus B (FVB) Mice |
|
|
104 | (1) |
|
DN in Spontaneous Models of T2DM |
|
|
105 | (1) |
|
|
105 | (1) |
|
|
105 | (6) |
9 Diabetic Neuropathy - Clinical |
|
111 | (18) |
|
|
|
111 | (1) |
|
Classification of Diabetic Neuropathies |
|
|
111 | (11) |
|
Distal Symmetric Polyneuropathy (DSPN) |
|
|
112 | (2) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
114 | (2) |
|
|
115 | (1) |
|
|
115 | (1) |
|
|
116 | (3) |
|
|
117 | (1) |
|
|
117 | (2) |
|
Treatment-Induced Neuropathy of Diabetes (TIND) |
|
|
119 | (1) |
|
|
119 | (1) |
|
|
120 | (1) |
|
Diabetic Radiculoplexopathy |
|
|
120 | (1) |
|
|
120 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (8) |
|
|
121 | (1) |
|
|
122 | (1) |
|
|
122 | (1) |
|
Summary of Management of Diabetic Neuropathy |
|
|
122 | (1) |
|
|
123 | (6) |
10 Diabetic Neuropathy - Research |
|
129 | (28) |
|
|
|
|
Basic and Translational Research in Diabetic Neuropathy |
|
|
129 | (17) |
|
Animal Models of Diabetic Neuropathy |
|
|
129 | (2) |
|
Basic Pathophysiology of Diabetic Neuropathy |
|
|
131 | (9) |
|
Changes in Redox Potential |
|
|
131 | (2) |
|
Role of Mitochondrial Dysfunction in Diabetic Neuropathy |
|
|
133 | (4) |
|
Protein Kinase C (PKC) and Neuropathy |
|
|
137 | (1) |
|
Advanced Glycation End Products |
|
|
137 | (1) |
|
Modifying Molecular Chaperones |
|
|
138 | (1) |
|
Inflammation and Neuropathy |
|
|
138 | (1) |
|
|
138 | (1) |
|
Metabotropic Glutamate Receptors (mGluRs) and Oxidative Injury |
|
|
139 | (1) |
|
Growth Factors and Diabetes |
|
|
139 | (1) |
|
Clinical Research in Diabetic Neuropathy |
|
|
140 | (18) |
|
Treatment of Hypertension |
|
|
141 | (1) |
|
Improved Glycemic Control |
|
|
141 | (1) |
|
Diet and Lifestyle Interventions |
|
|
142 | (2) |
|
|
144 | (1) |
|
Benfotiamine and Neuropathy |
|
|
145 | (1) |
|
Treatment of Neuropathic Pain |
|
|
145 | (1) |
|
|
146 | (1) |
|
|
147 | (10) |
11 Diabetic Foot - Clinical |
|
157 | (16) |
|
|
Introduction and Size of the Problem |
|
|
157 | (1) |
|
Pathogenesis of Diabetic Foot Complications |
|
|
158 | (1) |
|
|
158 | (1) |
|
Peripheral Vascular Disease |
|
|
158 | (1) |
|
|
159 | (1) |
|
|
159 | (1) |
|
|
160 | (1) |
|
Treatment of Neuropathic Diabetic Foot Ulcers: Offloading |
|
|
160 | (1) |
|
Treatment of PAD: Revascularization |
|
|
161 | (2) |
|
Diabetic Foot Infections (DFIs) |
|
|
163 | (3) |
|
|
163 | (1) |
|
|
163 | (1) |
|
|
164 | (2) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
167 | (1) |
|
Topical Negative Pressure Wound Therapy (NPWT) |
|
|
167 | (1) |
|
|
167 | (1) |
|
|
167 | (6) |
12 Diabetic Foot - Research |
|
173 | (28) |
|
|
|
|
173 | (1) |
|
Anatomy of the Skin and Microcirculation |
|
|
174 | (1) |
|
Structural Changes in the Microcirculation |
|
|
174 | (1) |
|
Functional Changes in the Microcirculation |
|
|
175 | (1) |
|
Functional Changes in the Diabetic Foot |
|
|
176 | (8) |
|
|
176 | (3) |
|
Endothelium-Dependent Vasodilation |
|
|
177 | (1) |
|
Endothelium-Independent Vasodilation |
|
|
178 | (1) |
|
|
179 | (1) |
|
Mechanisms of Endothelial Dysfunction |
|
|
180 | (4) |
|
Endothelial Dysfunction and Hyperglycemia |
|
|
180 | (2) |
|
Endothelial Dysfunction and Insulin Resistance |
|
|
182 | (1) |
|
Endothelial Dysfunction and Inflammation |
|
|
183 | (1) |
|
Pathophysiology of Diabetic Wound Healing |
|
|
184 | (2) |
|
|
184 | (1) |
|
|
184 | (2) |
|
Impaired Angiogenesis and Vasculogenesis |
|
|
186 | (1) |
|
|
186 | (1) |
|
Impaired Neuropeptide Signaling |
|
|
186 | (1) |
|
Adjunctive Treatment Options |
|
|
186 | (3) |
|
Bioengineered Skin Substitutes |
|
|
187 | (1) |
|
|
187 | (1) |
|
Hyperbaric Oxygen Therapy |
|
|
188 | (1) |
|
Negative Pressure Wound Therapy |
|
|
188 | (1) |
|
Electrical Stimulation and Shockwave Therapy |
|
|
189 | (1) |
|
Future Therapeutic Perspectives |
|
|
189 | (2) |
|
|
189 | (1) |
|
|
189 | (1) |
|
Norleu3-Angiotensin-(1-7) |
|
|
190 | (1) |
|
|
190 | (1) |
|
|
190 | (1) |
|
|
191 | (1) |
|
|
191 | (10) |
13 Coronary Microvascular Dysfunction in Diabetes - Clinical and Research |
|
201 | (20) |
|
|
|
|
|
201 | (4) |
|
Clinical Classification and Mechanisms of CMD |
|
|
202 | (1) |
|
|
203 | (2) |
|
Clinical Assessment of CMD |
|
|
205 | (7) |
|
Non-Invasive Imaging Technique for the Assessment of CMD |
|
|
205 | (2) |
|
Transthoracic Doppler Evaluation |
|
|
205 | (1) |
|
Contrast Echocardiography |
|
|
206 | (1) |
|
Cardiovascular Magnetic Resonance (CMR) Imaging |
|
|
206 | (1) |
|
Positron Emission Tomography (PET) |
|
|
207 | (1) |
|
Invasive Techniques for the Evaluation of CBF |
|
|
207 | (3) |
|
Indicator Dilution-Based Methods |
|
|
207 | (1) |
|
|
208 | (1) |
|
|
208 | (1) |
|
Intracoronary Doppler Flow Wire |
|
|
208 | (2) |
|
|
210 | (14) |
|
The Effects of Glucose-Lowering Drugs on CMD |
|
|
211 | (1) |
|
Future Perspectives for the Treatment of CMD in Diabetes |
|
|
211 | (1) |
|
|
212 | (9) |
14 Cerebral Microvascular Disease in Diabetes - Clinical and Research |
|
221 | |
|
|
|
|
221 | (1) |
|
Postmortem Studies of the Brain in Diabetes |
|
|
222 | (1) |
|
Cerebral Small Vessel Disease on MRI |
|
|
223 | (1) |
|
MRI-Measured Cerebral Small Vessel Disease in Type 1 Diabetic Patients |
|
|
224 | (3) |
|
White Matter Hyperintensities |
|
|
224 | (2) |
|
|
226 | (1) |
|
|
226 | (1) |
|
Type 2 Diabetes and Cerebral Small Vessel Disease |
|
|
227 | (4) |
|
|
227 | (1) |
|
White Matter Hyperintensities |
|
|
228 | (2) |
|
|
230 | (1) |
|
|
230 | (1) |
|
Clinical Impact of Cerebral Small Vessel Disease in Diabetes |
|
|
231 | (4) |
|
|
231 | (2) |
|
|
233 | (1) |
|
|
234 | (1) |
|
The Influence of Microvascular Disease on the Structure and Functioning of the Diabetic Brain |
|
|
235 | (4) |
|
|
236 | (1) |
|
|
237 | (2) |
|
Conclusions and Future Directions |
|
|
239 | (1) |
|
|
240 | |
Index |
|
24 | |